WO2000043549A1 - Lipophilic quenching of viral inactivating agents - Google Patents
Lipophilic quenching of viral inactivating agents Download PDFInfo
- Publication number
- WO2000043549A1 WO2000043549A1 PCT/US2000/001768 US0001768W WO0043549A1 WO 2000043549 A1 WO2000043549 A1 WO 2000043549A1 US 0001768 W US0001768 W US 0001768W WO 0043549 A1 WO0043549 A1 WO 0043549A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- moiety
- agent
- quenching
- lipophilic
- ethyleneimine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2796/00—Viruses not covered by groups C12N2710/00 - C12N2795/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2549/00—Reactions characterised by the features used to influence the efficiency or specificity
- C12Q2549/10—Reactions characterised by the features used to influence the efficiency or specificity the purpose being that of reducing false positive or false negative signals
- C12Q2549/125—Reactions characterised by the features used to influence the efficiency or specificity the purpose being that of reducing false positive or false negative signals using sterilising/blocking agents, e.g. albumin
Definitions
- the invention relates to methods for quenching electrophiles.
- the transmission of viral diseases e.g., hepatitis A, B, and C infections, acquired immunodeficiency syndrome, and cytomegalovirus infection
- Other biological compositions such as mammalian and hybridoma cell lines, products of cell lines, milk, colostrum, and sperm, can also contain infectious viruses.
- Screening donor biological compositions for viral markers can help reduce the transmission of viruses to recipients, but many screening methods are directed to only a few discrete viruses, and are therefore incomplete, and may also be less than 100% sensitive. It is therefore important to inactivate viruses contained in donor blood, blood products, or other biological compositions.
- ethyleneimine monomer and ethyleneimine oligomers are very effective viral inactivating agents.
- Methods for producing and using ethyleneimine oligomers for inactivating viruses in biological compositions are generally described in U.S.S.N. 08/835,446 (filed April 8, 1997), 08/521,245 (filed August 29, 1995), 08/855,378 (filed May 13, 1997), 09/005,606 (filed January 12, 1998), and 09/005,719 (filed January 12, 1998), which are hereby incorporated by reference.
- Ethyleneimine oligomers are themselves chemically active, and must therefore be rendered non-reactive before a product, such as blood, is used clinically.
- a viral inactivating compound such as ethyleneimine dimer
- a quenching agent is then added to inactivate the ethyleneimine dimer that remains after viral inactivation has taken place.
- the end result is a biological composition that is relatively free of infectious viruses, but that is contaminated with quenched inactivating agent and with quenching agent.
- the invention features a method of inactivating a contaminant, such as a virus, of a biological composition; the method includes the steps of: (a) contacting the biological composition with an inactivating agent including an aziridino moiety, such as ethyleneimine, an oligomer of ethyleneimine, or a haloderivative salt of either ethyleneimine or an oligomer of ethyleneimine, where a portion of the agent reacts with and inactivates the contaminant, and a portion of the agent remains unreacted; (b) contacting the product of step (a) with a lipophilic quenching agent including at least one quenching moiety, under conditions and for a time sufficient to allow the unreacted agent to bond covalently to the quenching moiety; and (c) separating the lipophilic quenching agent and the quenched inactivating agent from the biological composition.
- an inactivating agent including an aziridino moiety, such as ethyleneimine, an oligomer of ethylenei
- a preferred quenching moiety includes a nucleophilic moiety, such as a thiosulfate or thiophosphate moiety; the thiophosphate moiety may be part of an internucleotide linkage of an oligonucleotide sequence.
- the inactivating agent may be, for example, ethyleneimine, an oligomer of ethyleneimine, or a haloderivative salt of either ethyleneimine or an oligomer of ethyleneimine.
- the biological composition may be selected from the group consisting of whole mammalian blood, purified or partially purified blood proteins, blood cell proteins, milk, saliva, blood plasma, platelet- rich plasma, a plasma concentrate, a precipitate from any fractionation of plasma, a supernatant from any fractionation of plasma, a serum, a cryoprecipitate, a cryosupernatant, a cell lysate, a mammalian cell culture, a mammalian culture supernatant, a placental extract, a product of fermentation, a platelet concentrate, a leukocyte concentrate, semen, red blood cells, and a recombinant protein- containing composition produced in a transgenic mammal.
- the biological composition is whole human blood or human blood plasma.
- the invention features a method of quenching an electrophile; the method includes contacting the electrophile with a composition including at least one thiosulfate or thiophosphate moiety attached to a second lipophilic moiety, under conditions and for a time sufficient to allow the electrophile to bond covalently to the thiosulfate or thiophosphate moiety.
- a plurality of the thiosulfate or thiophosphate moieties are substituted with at least one C]_ 40 saturated or unsaturated hydrocarbon skeleton that is unsubstiruted or has between 1 and 4, inclusive, substituents, independently selected from the group consisting of hydroxyl, amino, cyano, and azido.
- the electrophile includes an aziridino moiety or a haloderivative salt.
- the electrophile may be ethyleneimine or an oligomer of ethyleneimine.
- the invention features a method of removing a viral inactivating agent from a biological composition; the method includes the steps of: (a) contacting the inactivating agent with a quenching agent that is coupled to a lipophilic moiety selected from the list consisting of linear, branched, or cyclic saturated or unsaturated hydrocarbons or esters with one to forty carbons, benzyl groups, or polycyclic aromatic groups, all of which may contain hydroxyl, amino, cyano, or azido substituents; and (b) removing the inactivating agent, the quenching agent, and the lipophilic moiety from the biological composition.
- a quenching agent that is coupled to a lipophilic moiety selected from the list consisting of linear, branched, or cyclic saturated or unsaturated hydrocarbons or esters with one to forty carbons, benzyl groups, or polycyclic aromatic groups, all of which may contain hydroxyl, amino, cyano, or azido substituents
- step (a) includes contacting the inactivating agent with the quenching agent under conditions and for a time sufficient to allow covalent bonds to form between the inactivating agent and the quenching agent.
- a preferred quenching agent includes a nucleophilic moiety, such as a thiosulfate or thiophosphate moiety.
- the invention features a compound comprising (a) a lipophilic moiety; and (b) a thiosulfate or thiophosphate moiety.
- the lipophilic moiety is selected from the list consisting of linear, branched, or cyclic saturated or unsaturated hydrocarbons or esters with one to forty carbons, benzyl groups, or polycyclic aromatic groups, all of which may contain hydroxyl, amino, cyano, or azido substituents.
- the compound may further include a reporter moiety, such as UV adsorbing or fluorescent groups.
- the thiophosphate moiety may be part of an internucleotide linkage of an oligonucleotide sequence.
- quenching moiety or “quenching agent” is meant a thiophosphate or a thiosulfate, or a compound containing a thiophosphate or a thiosulfate moiety that, when contacted with an electrophile, such as an ethyleneimine oligomer, is capable of rendering the contacted electrophile non- reactive.
- an electrophile such as an ethyleneimine oligomer
- biological composition is meant a composition containing cells or a composition containing one or more biological molecules, or a composition containing both cells and one or more biological molecules.
- Cell- containing compositions include, for example, mammalian blood, red cell concentrates, platelet concentrates, leukocyte concentrates, blood plasma, platelet-rich plasma, semen, placental extracts, mammalian cell culture or culture medium, products of fermentation, and ascites fluid.
- Biological compositions may also be cell-free, and contain at least one biological molecule.
- biological molecule any class of organic molecule normally found in living organisms including, for example, nucleic acids, polypeptides, post-translationally modified proteins (e.g., glycoproteins), polysaccharides, and lipids.
- Biological molecule-containing biological compositions include, for example, serum, blood cell proteins, blood plasma concentrate, blood plasma protein fractions, purified or partially purified blood proteins or other components, a supernatant or a precipitate from any fractionation of the plasma, purified or partially purified blood components (e.g., proteins or lipids), mammalian colostrum, milk, urine, saliva, a cell lysate, cryoprecipitate, cryosupernatant, or portion or derivative thereof, compositions containing proteins induced in blood cells, and compositions containing products produced in cell culture by normal or transformed cells (e.g., via recombinant DNA or monoclonal antibody technology).
- blood components e.g., proteins or lipids
- mammalian colostrum e.g., milk, urine, saliva, a cell lysate, cryoprecipitate, cryosupernatant, or portion or derivative thereof
- compositions containing proteins induced in blood cells e.g., via re
- lipophilic moiety is meant a moiety selected from the list consisting of linear, branched, or cyclic saturated or unsaturated hydrocarbons with one to forty carbons, benzyl groups, or polycyclic aromatic groups.
- reporter moiety is meant a UV adsorbing or fluorescent group which is added to the lipophilic quenching agent for the monitoring of removal of the lipophilic quenching agent and the quenched inactivating agent.
- viral inactivating conditions is meant the conditions under which the viral particles are incubated with the selective ethyleneimine oligomer inactivating agents of this invention, including, for example, time of treatment, pH, temperature, salt composition and concentration of selective inactivating agent so as to inactivate the viral genome to the desired extent.
- Viral inactivating conditions are selected from the conditions for selective modification of nucleic acids described in U.S. Patent Application Serial No. 08/855,378, hereby incorporated by reference.
- the invention provides new methods for the quenching of viral inactivating agents and the subsequent removal of the quenching and inactivating agents from a biological composition. This method results in a biological composition that is relatively free not only of contaminating viruses, but also relatively free of quenched (i.e., non-reactive) inactivating agent and unreacted quenching agent.
- the invention provides methods which are compatible with methods of removing solvent and detergent from protein- containing preparations which are virally-inactivated by a solvent/detergent method.
- Fig. 1 is a schematic illustration showing the preparation of a lipophilic quenching agent that contains a thiophosphate group.
- Fig. 2 is a schematic illustration showing several possible structures of lipophilic quenching agents.
- the T represents thymidine, which serves as an optional reporter moiety to allow for monitoring removal of quenching agent from biological compositions.
- Fig. 3 is a schematic illustration of quenching of an aziridino compound, PEN102, by thiophosphate bound to a lipophilic moiety.
- the invention provides general methods for quenching electrophiles with nucleophilic quenching agents, such as thiosulfate or thiophosphate moieties, that are modified so as to allow for the removal of the electrophile and the quenching agent from a biological composition.
- nucleophilic quenching agents such as thiosulfate or thiophosphate moieties
- a method of removal of quenching agent and quenched virus inactivating agent is through the use of nucleophiles, such as the thiosulfate or thiophosphate groups described above, which have attached to them lipophilic moieties. These lipophilic compounds can react with and quench electrophiles such as an ethyleneimine oligomer.
- This method has the added advantage that it is compatible with methods to remove solvent and detergent from protein- containing preparations which are virally-inactivated by the Solvent/Detergent procedure described by Budowsky et al., U.S.S.N. 09/005,719.
- Solvent/Detergent method of virus activation is compatible with the virus inactivation by compounds such as ethyleneimine monomer and ethyleneimine oligomer.
- compounds such as ethyleneimine monomer and ethyleneimine oligomer.
- the inactivation of viruses through the use of ethylene oligomer, followed by quenching and removal of the quenching and inactivating agents can be performed without the use of the Solvent/Detergent method.
- a thiophosphodiester e.g., a thiophosphodiester
- the substituent may be, for example, a linear, branched, or cyclic saturated or unsaturated hydrocarbon with one to forty carbons, a benzyl group, a polycyclic aromatic group, an unsubstituted alkyl group, or an alkyl group substituted with hydroxyl, amino, azido, or cyano groups.
- Polythiophosphate moieties i.e., moieties having two or more adjacent phosphate groups
- GDP guanosine diphosphate
- GTP guanosine triphosphate
- phosphate groups may be thiophosphate groups.
- guanosine triphosphate one, two, or all three of the phosphate groups may be thiophosphate groups.
- GDP or GTP may be attached to the lipophilic moiety, for example, at the 2' or the 3' hydroxyl group or to the heterocyclic base.
- the compositions of the invention can be prepared as described below in the Examples. They can also be prepared using other standard synthetic techniques of oligonucleotide synthesis, such as those described in Oligonucleotides and Analogs: A Practical Approach (Eckstein ed., IRL Press 1991). As an example, the quenching systems of the invention can be used as follows.
- a viral inactivating agent such as an ethyleneimine oligomer
- a biological composition as described in Budowsky, U.S.S.N. 08/855,378 and Budowsky et al., U.S.S.N. 90/005,606.
- the biological composition is contacted with quenching agent, lipophilic compounds containing thiosulfate or thiophosphate groups.
- the biological composition and the quenching agent are allowed to remain in contact for at least one hour, at room temperature and a pH of 7.0. A 10-fold excess of thiosulfate or thiophosphate groups per equivalent of ethyleneimine oligomer is used.
- the thiosulfate or thiophosphate groups react with the highly reactive moieties of the ethyleneimine compounds and become covalently linked to the ethyleneimine compounds or their haloderivative salts.
- the quenched ethyleneimine compounds are removed as well.
- the end result is a biological composition that is substantially free of infectious viruses, quenched ethyleneimine compounds, and quenching agent.
- a biological composition containing the inactivating agent ethyleneimine dimer can be quenched with sodium thiosulfate.
- the biological composition may include any of a number of substances.
- matrices include whole mammalian blood, purified or partially purified blood proteins, blood cell proteins, milk, saliva, blood plasma, platelet-rich plasma, a plasma concentrate, a precipitate from any fractionation of plasma, a supernatant from any fractionation of plasma, a serum, a cryoprecipitate, a cryosupernatant, a cell lysate, a mammalian cell culture, a mammalian culture supernatant, a placental extract, a product of fermentation, a platelet concentrate, a leukocyte concentrate, semen, and red blood cells.
- Other biological matrices include those containing recombinant proteins produced in transgenic mammals.
- the biological composition may include a protein that has been expressed in the milk of a transgenic mammal.
- Methods for producing such proteins are described, for example, in Wright et al., BioTechnology 9:830-834 (1991) and the references cited therein.
- Example 1 Preparation of a lipophilic quencher that contains a thiosulfate or thiophosphate group
- a lipophilic quenching agent of the invention is described in Fig. 1.
- a lipophilic molecule (indicated as R) containing a hydroxyl group is derivatized with a phosphorylating agent.
- the phosphite group of the phosphorylated lipophilic molecule is oxidized to form a thiophosphate ester, which is cleaved with acid to provide a thiophosphate moiety.
- the product is a thiophosphate moiety that is attached to a lipophilic moiety.
- Many lipophilic moieties can be used for the production of the compositions of the invention.
- Example moieties are shown in Fig. 2.
- a common procedure to remove the solvent and detergent is a combination of an extraction step, such as with soybean oil, and a hydrophobic column chromatography step.
- an extraction step such as with soybean oil
- a hydrophobic column chromatography step it is preferred that the quenching agent and the quenched inactivating agent are readily extracted into soybean oil and able to bind to a hydrophobic column.
- the following properties identify a lipophilic moiety as being appropriate.
- One preferred property is extractability from aqueous solutions through the use of an oil, such as, for example, soybean oil.
- Another preferred property is affinity to a hydrophobic column, such as, for example, a C1-C18 column.
- Example 2 Quenching of an aziridino compound with a thiosulfate or thiophosphate group that is bound to a lipophilic moiety
- a nucleophilic thiophosphate group which is bound to a lipophilic moiety, attacks and quenches the aziridino compound; the aziridino compound is not only rendered inactive, it also remains bonded to the quenching agent through covalent bonds.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00908354A EP1147227A4 (en) | 1999-01-25 | 2000-01-24 | Lipophilic quenching of viral inactivating agents |
AU29714/00A AU2971400A (en) | 1999-01-25 | 2000-01-24 | Lipophilic quenching of viral inactivating agents |
CA002360803A CA2360803A1 (en) | 1999-01-25 | 2000-01-24 | Lipophilic quenching of viral inactivating agents |
JP2000594957A JP2002535343A (en) | 1999-01-25 | 2000-01-24 | Termination of the lipophilic reaction of virus inactivators |
HK02102944.1A HK1043156A1 (en) | 1999-01-25 | 2002-04-18 | Lipophilic quenching of viral inactivating agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/237,136 | 1999-01-25 | ||
US09/237,136 US6150109A (en) | 1999-01-25 | 1999-01-25 | Lipophilic quenching of viral inactivating agents |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000043549A1 true WO2000043549A1 (en) | 2000-07-27 |
Family
ID=22892485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/001768 WO2000043549A1 (en) | 1999-01-25 | 2000-01-24 | Lipophilic quenching of viral inactivating agents |
Country Status (7)
Country | Link |
---|---|
US (2) | US6150109A (en) |
EP (1) | EP1147227A4 (en) |
JP (1) | JP2002535343A (en) |
AU (1) | AU2971400A (en) |
CA (1) | CA2360803A1 (en) |
HK (1) | HK1043156A1 (en) |
WO (1) | WO2000043549A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005002570A1 (en) * | 2003-06-27 | 2005-01-13 | V.I. Technologies, Inc. | Use of an aziridino compound to selectively inactivate parasites in biological compositions |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5691132A (en) * | 1994-11-14 | 1997-11-25 | Cerus Corporation | Method for inactivating pathogens in red cell compositions using quinacrine mustard |
WO1999034839A1 (en) | 1998-01-06 | 1999-07-15 | Cerus Corporation | Methods for quenching pathogen inactivators in biological materials |
US6150109A (en) | 1999-01-25 | 2000-11-21 | V. I. TECHNOLOGIES, Inc. | Lipophilic quenching of viral inactivating agents |
US20020131958A1 (en) * | 2001-01-22 | 2002-09-19 | John Chapman | Method for purifying a biological composition |
WO2006050328A1 (en) * | 2004-10-29 | 2006-05-11 | Cerus Corporation | Improved quenching methods for red blood cell inactivation process |
AU2009233807B2 (en) | 2008-04-09 | 2014-11-27 | Cerus Corporation | Improved quenching methods for red blood cell pathogen inactivation |
US9694030B2 (en) * | 2014-10-17 | 2017-07-04 | Frederick J. Sawaya | Composition for treatment, inhibition and attenuation of virus |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652359A (en) * | 1993-12-02 | 1997-07-29 | Epoch Pharmaceuticals, Inc. | Oligonucleotides containing n-methyl thiolated bases having antiviral activity |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3501557A (en) * | 1966-05-02 | 1970-03-17 | Exxon Research Engineering Co | Process for preparing 2-aminoethylthiophosphate salts |
US3487157A (en) | 1966-10-31 | 1969-12-30 | Allied Chem | Novel n-substituted aziridine compositions and method for combating microorganisms therewith |
DE1924303A1 (en) | 1969-05-13 | 1970-12-17 | Bayer Ag | AEthylaethyleneimine as inactivating agent |
SU382638A1 (en) * | 1971-09-03 | 1973-05-25 | Институт биохимии Литовской ССР , Институт элементоорганических соединений СССР | METHOD OF OBTAINING 8-2 |
JPS6014027B2 (en) * | 1980-02-04 | 1985-04-11 | 相互薬工株式会社 | Method for producing cysteamine-S-substituted product and its derivatives |
US4429045A (en) | 1980-07-30 | 1984-01-31 | Norden Laboratories, Inc. | Rabies virus adapted for growth in swine testicle cell culture |
US4515906A (en) * | 1983-02-28 | 1985-05-07 | Bend Research, Inc. | Anisotropic microporous supports impregnated with polymeric ion-exchange materials |
US4567042A (en) | 1983-06-15 | 1986-01-28 | American Home Products Corporation | Inactivated canine coronavirus vaccine |
JP2668214B2 (en) | 1987-08-03 | 1997-10-27 | 益代 中井 | AIDS treatment |
US5547576A (en) | 1992-07-06 | 1996-08-20 | Terumo Kabushiki Kaisha | Pathogenic substance removing material and a blood filter containing the material |
JPH0680520A (en) | 1992-09-02 | 1994-03-22 | Terumo Corp | Virus inactivating agent |
US5744362A (en) * | 1994-05-31 | 1998-04-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US5691132A (en) | 1994-11-14 | 1997-11-25 | Cerus Corporation | Method for inactivating pathogens in red cell compositions using quinacrine mustard |
US6177441B1 (en) | 1995-06-05 | 2001-01-23 | Cerus Corporation | Treating red blood cell solutions with anti-viral agents |
EP0773716A4 (en) | 1995-06-07 | 1999-08-04 | Cerus Corp | Treating red blood cell solutions with anti-viral agents |
WO1996039820A1 (en) | 1995-06-07 | 1996-12-19 | Cerus Corporation | Methods of inactivating leukocytes and inhibiting cytokine production in blood products |
US6136586A (en) | 1995-08-29 | 2000-10-24 | Vi Technologies, Inc. | Methods for the selective modification of viral nucleic acids |
US6114108A (en) | 1995-08-29 | 2000-09-05 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of viral nucleic acids |
US20020034724A1 (en) | 1995-08-29 | 2002-03-21 | Edson Clark M. | Methods to selectively inactivate microorganisms in biological compositions |
AU6267596A (en) | 1995-12-14 | 1997-07-03 | Steritech, Inc. | Inactivation of non-enveloped virus |
JP3069949B2 (en) | 1996-10-09 | 2000-07-24 | 日精樹脂工業株式会社 | Input device of injection molding machine |
WO1998030545A1 (en) | 1997-01-06 | 1998-07-16 | Cerus Corporation | Frangible compounds for pathogen inactivation |
JP4630405B2 (en) | 1997-01-06 | 2011-02-09 | セラス コーポレーション | Method and apparatus for reducing small organic compounds from blood products |
US6093725A (en) | 1997-01-06 | 2000-07-25 | Cerus Corporation | Frangible compounds for pathogen inactivation |
US5891705A (en) | 1997-04-08 | 1999-04-06 | Pentose Pharmaceuticals, Inc. | Method for inactivating a virus |
US6093564A (en) * | 1997-10-03 | 2000-07-25 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of nucleic acids |
US6352695B1 (en) | 1997-10-03 | 2002-03-05 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of nucleic acids |
US6369048B1 (en) | 1998-01-12 | 2002-04-09 | V.I. Technologies, Inc. | Methods and compositions for inactivating viruses |
US6617100B2 (en) * | 1998-09-25 | 2003-09-09 | V.I. Technologies, Inc. | Solid phase quenching systems |
WO2000018969A1 (en) | 1998-09-25 | 2000-04-06 | Pentose Pharmaceuticals, Inc. | Methods to selectively inactivate viruses in biological compositions |
US6403359B1 (en) | 1998-09-25 | 2002-06-11 | V. I. TECHNOLOGIES, Inc. | Solid phase quenching systems |
US6150109A (en) | 1999-01-25 | 2000-11-21 | V. I. TECHNOLOGIES, Inc. | Lipophilic quenching of viral inactivating agents |
-
1999
- 1999-01-25 US US09/237,136 patent/US6150109A/en not_active Expired - Fee Related
-
2000
- 2000-01-24 AU AU29714/00A patent/AU2971400A/en not_active Abandoned
- 2000-01-24 EP EP00908354A patent/EP1147227A4/en not_active Withdrawn
- 2000-01-24 WO PCT/US2000/001768 patent/WO2000043549A1/en not_active Application Discontinuation
- 2000-01-24 JP JP2000594957A patent/JP2002535343A/en active Pending
- 2000-01-24 CA CA002360803A patent/CA2360803A1/en not_active Abandoned
- 2000-09-06 US US09/656,243 patent/US6617101B1/en not_active Expired - Fee Related
-
2002
- 2002-04-18 HK HK02102944.1A patent/HK1043156A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652359A (en) * | 1993-12-02 | 1997-07-29 | Epoch Pharmaceuticals, Inc. | Oligonucleotides containing n-methyl thiolated bases having antiviral activity |
Non-Patent Citations (2)
Title |
---|
BAHNEMANN,: "Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimene", VACCINE,, vol. 8, August 1990 (1990-08-01), pages 299 - 304, XP002926717 * |
BUDOWSKY ET AL.: "Principles of Selective Inactivation of the Viral Genome: Dependence of the Rate of Viral RNA Modification on the Number of Protonizable Groups in Ethylenimine Oligomers", VACCINE RESEARCH,, vol. 5, no. 1, November 1996 (1996-11-01), pages 29 - 39, XP002926716 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005002570A1 (en) * | 2003-06-27 | 2005-01-13 | V.I. Technologies, Inc. | Use of an aziridino compound to selectively inactivate parasites in biological compositions |
Also Published As
Publication number | Publication date |
---|---|
JP2002535343A (en) | 2002-10-22 |
EP1147227A4 (en) | 2004-06-16 |
HK1043156A1 (en) | 2002-09-06 |
US6617101B1 (en) | 2003-09-09 |
EP1147227A1 (en) | 2001-10-24 |
US6150109A (en) | 2000-11-21 |
CA2360803A1 (en) | 2000-07-27 |
AU2971400A (en) | 2000-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101676268B (en) | Frangible compounds for pathogen inactivation | |
US4446237A (en) | Method for detection of a suspect viral deoxyribonucleic acid in an acellular biological fluid | |
JP4643004B2 (en) | Method for quenching pathogen inactivating agents in biomaterials | |
Schultze et al. | Neuraminidase treatment of avian infectious bronchitis coronavirus reveals a hemagglutinating activity that is dependent on sialic acid-containing receptors on erythrocytes | |
AU4829999A (en) | Methods for rapidly identifying small organic ligands | |
US6150109A (en) | Lipophilic quenching of viral inactivating agents | |
JPH02198561A (en) | Removing process for working-chemical substance from unstable organism material mixture using hydrophobic interaction chromatography | |
US6774123B1 (en) | Methods and compositions for inactivating viruses | |
ATE219093T1 (en) | METHOD FOR ISOLATION OF ANIONIC ORGANIC SUBSTANCES FROM AQUEOUS SYSTEMS USING CATIONIC POLYMERNANOPARTICLES | |
US20030113704A1 (en) | Methods for inactivation of pathogens in biological materials | |
US6720136B2 (en) | Solid phase quenching systems | |
US6617100B2 (en) | Solid phase quenching systems | |
US5696236A (en) | Method for the removal of viruses from protein solutions | |
EP1508039A2 (en) | Method for discovering new infectious particles | |
WO1994029479A1 (en) | Oligonucleotides which inhibit hiv protease function | |
EP0937735B1 (en) | A method for the removal of causative agent(s) of transmissible spongiform encephalopathies from protein solutions | |
US20020034724A1 (en) | Methods to selectively inactivate microorganisms in biological compositions | |
Willkommen | 1d Virus transmission by virus-inactivated plasma products | |
EP0308724B1 (en) | Use of a immunistimulating biologic to manufacture a medicament to treat human immunodeficiency virus | |
US5912328A (en) | Method for the removal of viruses from protein solutions | |
US20030019763A1 (en) | Apparatus and method for separation of biological contaminants | |
Killington | Preparation of antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN IL JP NO NZ PL SG |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2360803 Country of ref document: CA Ref country code: CA Ref document number: 2360803 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 594957 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000908354 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000908354 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000908354 Country of ref document: EP |